Objective: To analyze the new drugs approved by the U.S. FDA in 2023 and compare them with the new drug approvals in China during the same year, providing a reference for the pharmaceutical industry. Methods: By reviewing the "2023 New Drug Approval Summary Report" released by the US FDA CDER, the "2023 Drug Evaluation Report" released by China's CDE, Drugs@FDA database, drug approvals published by the NMPA, and publicly available information on marketed drugs from the CDE, combined with relevant literature, data on new drugs approved by the FDA in 2023 were collected and statistically analyzed, and compared with the relevant situation in China. Results and Conclusion: In 2023, the FDA approved a total of 55 new drugs, including treatments for various medical fields such as oncology, genetic/rare diseases, and neurological disorders. 51% of the new drugs received orphan drug designation, 36% of the new drugs were recognized as "first-in-class", and 65% of the new drug approvals utilized at least one expedited program. Furthermore, the companies that have been approved for new drugs cover a wide range, from large pharmaceutical giants to small and medium-sized biotechnology firms, with varying numbers of new drug approvals. China approved 74 new drugs, and the breadth and diversity of disease fields are comparable to those of the FDA. However, the innovation of new drugs and the development of rare disease drugs need to be improved. 38% of the new drug approvals in China included at least one expedited marketing process. The time required for new drug review has decreased compared to 2022, but the one-time pass rate has also decreased, reflecting the increasing strictness of regulation. Pharmaceutical companies need to improve the quality of their application materials, and regulatory authorities need to improve drug regulation laws, strengthen the training and education of drug regulatory personnel, and enhance their professional level and international perspective.
Ma Qiaoning
,
Zheng Yang
,
Yuan Yanfang
,
Wang Wenya
. Comparative Analysis of New Drugs Approved by the United States and China in 2023[J]. Chinese Pharmaceutical Affairs, 2024
, 38(11)
: 1235
-1246
.
DOI: 10.16153/j.1002-7777.20240547
[1] U.S.Food and Drug Administration. Advancing Health Through Innovation: New Drug Therapy Approvals 2023[EB/OL].(2024-06-18)[2024-06-25]. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023.
[2] U.S.Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs[DB/OL].[2024-06-25]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
[3] U.S. Food and Drug Administration. Advancing Health Through Innovation: New Drug Therapy Approvals2022[EB/OL].(2024-03-18)[2024-06-25]. https://www.fda.gov/media/164429/download?attachment.
[4] de la Torre BG,Albericio F. The Pharmaceutical Industry in 2022:An Analysis of FDA Drug Approvals from the Perspective of Molecules[J]. Molecules,2023,28(3):1038-1050.
[5] 国家药品监督管理局药品审评中心. 2023年度药品审评报告[EB/OL].(2024-02-04)[2024-07-20]. https://www.cde.org.cn/main/news/viewInfoCommon/9506710a7471174ab169e98b0bbb9e23.
[6] 国家药品监督管理局. 药品批件发布[EB/OL].[2024-07-20]. https://www.nmpa.gov.cn/zwfw/zwfwpjfbzs/pjfbzsyp/index.html.
[7] 国家药品监督管理局药品审评中心. 上市药品信息[DB/OL].[2024-07-20]. https://www.cde.org.cn/main/xxgk/listpage/b40868b5e21c038a6aa8b4319d21b07d.
[8] 杨景舒,杨殿政,杨悦. 1983-2019年美国孤儿药激励政策评价[J]. 中国新药杂志,2021,30(21):1921-1927.
[9] U.S.Food and Drug Administration. NDA217026[DB/OL].[2024-06-27]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
[10] U.S.Food and Drug Administration. NDA216951[DB/OL].[2024-06-27]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
[11] U.S.Food and Drug Administration. NDA216675[DB/OL].[2024-06-27]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
[12] U.S.Food and Drug Administration. NDA217188[DB/OL].[2024-06-27]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
[13] U.S.Food and Drug Administration. NDA216718[DB/OL].[2024-06-27]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
[14] U.S.Food and Drug Administration. BLA761342[DB/OL].[2024-06-27]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
[15] U.S.Food and Drug Administration. NDA216578[DB/OL].[2024-06-27]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
[16] U.S.Food and Drug Administration. NDA217603[DB/OL].[2024-06-27]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
[17] U.S. Food and Drug Administration. Guidance for Industry:Expedited Programs for Serious Conditions Drugs and Biologics[EB/OL].(2023-11-28)[2024-06-28]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics.
